ONCBeOne Medicines Ltd - ADR

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA (zanubrutinib) plus rituximab versus bendamustine plus...

On June 18, a recent SEC filing unveiled that Henry Chan Lee, SVP at BeOne Medicines (NASDAQ:ONC) made an insider sell. What Happened: Lee's decision to sell 590 shares of BeOne Medicines was revealed in a Form 4read more...

It was reported on June 18, that Xiaobin Wu, President and COO at BeOne Medicines (NASDAQ:ONC) executed a significant insider sell, according to an SEC filing. What Happened: Wu opted to sell 1,357 shares of BeOneread more...

Revealing a significant insider sell on June 18, JOHN OYLER, Chief Executive Officer at BeOne Medicines (NASDAQ:ONC), as per the latest SEC filing. What Happened: OYLER's recent move involves selling 3,693 shares ofread more...

Revealing a significant insider sell on June 18, Lai Wang, President at BeOne Medicines (NASDAQ:ONC), as per the latest SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission onread more...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after...

BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BeOne Medicines Ltd. (BeOne) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29June 2, Chicago). These data underscore the...